# Re-evaluation Task: TN-002

## Context
- **Case ID**: TN-002
- **Cancer type**: Locally advanced oral tongue squamous cell carcinoma (OTSCC) with mandible invasion
- **Stage**: Stage IVA (T4aN2bM0, AJCC 8th edition)
- **Molecular profile**: PD-L1 CPS 15, TP53 mutated, CDKN2A loss (homozygous deletion), PIK3CA mutated
- **Report file**: experiment_reports\TN-002_report.json
- **Current score**: 86/100
- **Gap analysis (local GPU)**: The most critical gaps in the TN-002 report are the lack of data on Pembrolizumab (KEYNOTE-689 Regimen) and Neoadjuvant TPF Induction Chemotherapy (Docetaxel + Platinum + 5-FU), as including this information would provide a more comprehensive understanding of treatment outcomes for patients with head and neck squamous cell carcinoma. Filling these gaps will improve the score by providing valuable insights into the efficacy and safety of these treatments, allowing researchers to better understand their potential benefits and limitations in the context of HNSCC.

## Current dimension scores
| Dimension | Score | % of max |
|---|---|---|
| evidence_depth                      |  13/25  |  52.0% |
| clinical_relevance                  |   9/10  |  90.0% |
| rating_calibration                  |  14/15  |  93.3% |
| structural_integrity                |  15/15  | 100.0% |
| tier_coverage                       |  10/10  | 100.0% |
| source_quality                      |  15/15  | 100.0% |
| combo_supportive_coverage           |  10/10  | 100.0% |

## Target dimension: `evidence_depth` (52.0% of max)

## Your instructions

Read the full report JSON at `experiment_reports\TN-002_report.json`.

Your task: Fill missing evidence fields in `treatments[].key_evidence`.

For each treatment where these are null or missing, search and fill:
- `key_evidence.study_name` — full trial name
- `key_evidence.year` — publication year
- `key_evidence.sample_size` — numeric patient count
- `key_evidence.os_months.treatment` — median OS in treatment arm (months)
- `key_evidence.os_months.control` — median OS in control arm (months)
- `key_evidence.os_months.hazard_ratio` — HR from primary analysis
- `key_evidence.os_months.p_value` — p-value from OS analysis
- `key_evidence.pfs_months.treatment` — median PFS treatment arm
- `key_evidence.pfs_months.control` — median PFS control arm

Rules:
- Only fill with data you can verify from published trials
- Set to null (not omit) if genuinely unavailable after searching
- Do NOT fabricate or estimate numbers

Return the corrected `treatments` array only.

## Output format

Return a valid JSON object containing ONLY the corrected section (e.g., `{"treatments": [...]}` or `{"sources": [...]}`).

Do NOT return the full report — only the corrected array. The runner will merge it back.

After returning the JSON, add one line:
`SCORE_IMPACT: <estimated new score>/100`

## Report JSON (for reference)

```json
{
  "report_metadata": {
    "generated_date": "2026-03-23",
    "cancer_type": "Locally advanced oral tongue squamous cell carcinoma (OTSCC) with mandible invasion",
    "stage": "Stage IVA (T4aN2bM0, AJCC 8th edition)",
    "molecular_profile": [
      "PD-L1 CPS 15",
      "TP53 mutated",
      "CDKN2A loss (homozygous deletion)",
      "PIK3CA mutated"
    ]
  },
  "treatments": [
    {
      "rank": 1,
      "name": "Perioperative Pembrolizumab (KEYNOTE-689 Regimen)",
      "category": "Immunotherapy — FDA Approved (Perioperative)",
      "composite_rating": 8.7,
      "rating_breakdown": {
        "evidence_level": {
          "score": 9,
          "rationale": "Phase 3 RCT (KEYNOTE-689, n=714) demonstrated statistically significant EFS improvement. FDA approved June 13, 2025 for PD-L1 CPS>=1 resectable locally advanced HNSCC. First FDA approval in nearly two decades for this patient population"
        },
        "survival_benefit": {
          "score": 9,
          "rationale": "Median EFS 59.7 months vs 29.6 months (HR 0.70, 95% CI 0.55-0.89, p=0.0014). 36-month EFS rate 60% vs 46%. Doubled median EFS. OS data not yet mature but no detriment observed. Represents a paradigm shift in locally advanced HNSCC management"
        },
        "accessibility": {
          "score": 10,
          "rationale": "FDA approved since June 2025. Pembrolizumab is widely available globally. NCCN Category 1 recommendation for PD-L1 CPS>=1. Insurance coverage established for this indication"
        },
        "safety_profile": {
          "score": 6,
          "rationale": "Most common AEs: stomatitis (48%), radiation skin injury (40%), weight loss (36%), fatigue (33%). Serious AEs in 38% during adjuvant phase. Immune-mediated AEs manageable. Must monitor for surgical delay risk. Diabetes requires careful immune AE monitoring (risk of immune-mediated diabetes exacerbation)"
        },
        "biomarker_match": {
          "score": 9,
          "rationale": "Requires PD-L1 CPS>=1. Patient has PD-L1 CPS 15 — well above threshold. Higher CPS associated with greater benefit in KEYNOTE-689 subgroup analyses. Excellent biomarker match"
        }
      },
      "mechanism_of_action": "Pembrolizumab is an anti-PD-1 monoclonal antibody that blocks the PD-1/PD-L1 immune checkpoint, restoring T-cell-mediated antitumor immunity. Neoadjuvant dosing (2 cycles pre-surgery) primes the immune response while tumor antigens are present in vivo. Adjuvant dosing with radiation (+/- cisplatin) and subsequent maintenance eliminates residual micrometastatic disease through sustained immune surveillance.",
      "key_evidence": {
        "study_name": "KEYNOTE-689 Phase 3 RCT",
        "journal": "AACR Annual Meeting / Merck Press Release",
        "year": 2025,
        "sample_size": 714,
        "os_months": {
          "treatment": 59.7,
          "control": 29.6,
          "hazard_ratio": 0.7,
          "p_value": 0.0014
        },
        "pfs_months": {
          "treatment"
... (truncated — read full file from experiment_reports\TN-002_report.json)
```
